Cullinan Therapeutics
CGEM
146 hedge funds and large institutions have $799M invested in Cullinan Therapeutics in 2024 Q4 according to their latest regulatory filings, with 30 funds opening new positions, 54 increasing their positions, 36 reducing their positions, and 20 closing their positions.
50% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 20
50% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 36
29% more funds holding in top 10
Funds holding in top 10: 7 → 9 (+2)
7% more funds holding
Funds holding: 137 → 146 (+9)
4% less capital inflows, than outflows
Capital inflows: $118M | Capital outflows: $124M
1.66% less ownership
Funds ownership: 112.79% → 111.13% (-1.7%)
62% less call options, than puts
Call options by funds: $559K | Put options by funds: $1.45M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
+$18M |
| 2 |
OrbiMed
New York
|
+$12.5M |
| 3 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
+$12.2M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$10.5M |
| 5 |
Blue Owl Capital Holdings
New York
|
+$5.17M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Paradigm Biocapital Advisors
New York
|
-$38.9M |
| 2 |
Holocene Advisors
New York
|
-$25.7M |
| 3 |
Avidity Partners Management
Dallas,
Texas
|
-$7.11M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$5.78M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$4.68M |
CGEM Hedge Fund Activity: Q4 2024 in Review
146 of the 7,628 institutional investors tracked by Wall St. Rank reported a position in Cullinan Therapeutics (CGEM) for Q4 2024, worth a combined $799M — down 27% from $1.09B a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new CGEM positions and 20 closed out — a net gain of 10 holders — while 54 added to existing stakes and 36 trimmed.
The largest buyer was Kynam Capital Management, opening a new position worth an estimated $18M. The largest seller was Paradigm Biocapital Advisors, exiting entirely with an estimated $38.9M sold.
- 146 institutional investors held Cullinan Therapeutics (CGEM) as of Q4 2024, up from 137 in Q3 2024.
- Funds reported $799M of Cullinan Therapeutics stock for Q4 2024, down 27% quarter-over-quarter.
- 30 funds opened new Cullinan Therapeutics positions in Q4 2024 and 20 closed out, a net change of +10 holders.
- The largest Cullinan Therapeutics buyer in Q4 2024 was Kynam Capital Management, an estimated $18M added.
- The largest Cullinan Therapeutics seller in Q4 2024 was Paradigm Biocapital Advisors, an estimated $38.9M sold.
Based on aggregated 13F filings for Q4 2024.